TickerFacts.

Halozyme Therapeutics, Inc. (HALO): Shares Outstanding

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2018-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

117.78M
As of 2025-12-31
114.04M
As of 2026-06-30
-4.5%
3-year compound annual growth
-2.7%
5-year compound annual growth
144.73M2010-12-31: 100.58M2011-12-31: 103.99M2012-12-31: 112.71M2013-12-31: 114.53M2014-12-31: 125.72M2015-12-31: 128.15M2016-12-31: 129.50M2017-12-31: 142.79M2018-12-31: 144.73M2019-12-31: 136.71M2020-12-31: 135.03M2021-12-31: 137.50M2022-12-31: 135.15M2023-12-31: 126.77M2024-12-31: 123.14M2025-12-31: 117.78M117.78M
2010-12-31 Shares Outstanding (shares) 2025-12-31
Period endedShares OutstandingChange YoYSource filing
2025-12-31117.78M-4.3%2026-02-17, Balance as of period end
2024-12-31123.14M-2.9%2026-02-17, Balance as of period end
2023-12-31126.77M-6.2%2025-02-18, Balance as of period end
2022-12-31135.15M-1.7%2024-02-20, Balance as of period end
2021-12-31137.50M+1.8%2023-02-21, Balance as of period end
2020-12-31135.03M-1.2%2022-02-22, Balance as of period end
2019-12-31136.71M-5.5%2021-02-23, Balance as of period end
2018-12-31144.73Mn/c2020-02-24, Balance as of period end
2017-12-31142.79M+10.3%2019-02-21, Balance as of period end
2016-12-31129.50M+1.1%2018-02-20, Balance as of period end
2015-12-31128.15M+1.9%2017-02-28, Balance as of period end
2014-12-31125.72M+9.8%2016-02-29, Balance as of period end
2013-12-31114.53M+1.6%2015-03-02, Balance as of period end
2012-12-31112.71M+8.4%2014-02-28, Balance as of period end
2011-12-31103.99M+3.4%2013-03-01, Balance as of period end
2010-12-31100.58Mn/a2012-03-12, Balance as of period end